menu
    • menu
    [{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"PALADIN LABS","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endo International \/ Endo International","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Endo International \/ Endo International","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Nevakar","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Gabapentin","moa":"CaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Endo International","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Endo International","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Taiwan Liposome Company","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Rheumatology","graph2":"Phase III","graph3":"Endo International","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Endo International"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum-aaes","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bismuth Potassium Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Argatroban","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Bivalirudin","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ MAIA Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ MAIA Biotechnology"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Neostigmine Methylsulfate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Premier"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bivalirudin","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Endo International

    Menu

    Endo International

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen,Famotidine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

                            Details : Duexis-Generic (ibuprofen-famotidine) version will commercialize by the Endo. The combination medication is used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis.

                            Brand Name : Duexis-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Ibuprofen,Famotidine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

                            Details : Xcopri (cenobamate) is a positive allosteric modulator of the GABAA ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.

                            Brand Name : Xcopri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches Colchicine Capsules, Generic Version of MITIGARE®

                            Details : Colchicine capsule (0.6 mg) is a generic version of Hikma's Mitigare , it is indicated for prophylaxis of gout flares in adults. This is the first generic colchicine capsule approved by USFDA.

                            Brand Name : Mitigare-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bivalirudin

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches Bivalirudin Injection in Ready-to-Use Vials

                            Details : Bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.

                            Brand Name : Angiomax RTU

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 18, 2023

                            Lead Product(s) : Bivalirudin

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Premier

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage

                            Details : Under the collaboration, Endo's Par Sterile Products business will supply Pitocin® (oxytocin injection, USP) vials through Premier's ProvideGx® and PremierProRx® programs. Pitocin® is used to induce labor in pregnant women.

                            Brand Name : Pitocin

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 17, 2023

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Premier

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Announces Approval of XCOPRI (cenobamate tablets) in Canada

                            Details : XCOPRI™ (cenobamate tablets) inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel, which is used for partial-onset seizures in adults with epilepsy.

                            Brand Name : Xcopri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2023

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Posaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches First Generic Version of Noxafil (posaconazole) Injection

                            Details : Posaconazole injection is the inhibition of cytochrome P-450, which is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromise.

                            Brand Name : Noxafil-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2023

                            Lead Product(s) : Posaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches PREVDUO (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approve...

                            Details : PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.

                            Brand Name : Prevduo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bivalirudin

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : MAIA Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials

                            Details : The agreement aims to distribute Angiomax RTU (bivalirudin) injection, a direct thrombin inhibitor used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty, in the U.S.

                            Brand Name : Angiomax RTU

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 24, 2023

                            Lead Product(s) : Bivalirudin

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : MAIA Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Argatroban

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

                            Details : Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.

                            Brand Name : Argatroban-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 17, 2023

                            Lead Product(s) : Argatroban

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth